Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-4.65M |
| Operating Margin | 0.00% |
| Return on Equity | -662.00% |
| Return on Assets | -54.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.29 |
| Price-to-Book | 1.01 |
| Price-to-Sales (TTM) | 15.86 |
| EV/Revenue | 72.64 |
| EV/EBITDA | 1.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 531,970 |
| Float | 528,860 |
| % Insiders | 0.28% |
| % Institutions | 5.76% |
Volatility is currently contracting
CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced the nomination of Patricia Gauthier, MBA, LL.B.
hVIVO PLC's (AIM:HVO) consultancy contract with Decoy Therapeutics, announced on Monday, is a small deal by any financial measure, but Peel Hunt's reading of it points to something more strategically significant for the AIM-listed contract research organisation. The agreement covers a wide range of services to support Decoy's development of its Designable Multi-Antiviral candidates, a novel antiviral category targeting shared mechanisms across multiple respiratory viruses with a single, adaptable therapeutic approach.
hVIVO PLC (AIM:HVO), the clinical development company specialising in human challenge trials, has signed a consultancy contract with Decoy Therapeutics to support the development of a novel class of broad-spectrum respiratory antivirals. The engagement covers translational modelling, regulatory strategy, chemistry, manufacturing and controls consulting, non-clinical development support, and preparation of clinical and regulatory documentation for submissions to European and UK regulators, including the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency.
Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic CAMBRIDGE, Mass., June 1, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a pre-clinical-stage biotechnology company pioneering a new category of antivirals, today announced the execution of a strategic development initiative designed to support the advancement of the company's Designable Multi-Antiviral (D-MAV) candidates into Phase 1 first-in-human and Phase 2a human proof-of-concept studies.
Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development NEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a clinical-stage biotechnology company pioneering a new category of antivirals, today announced the appointment of Brad L.
Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development Transcript
Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billion-dollar antiviral markets Company to participate in Virtual Investor Closing Bell event to discuss pathforward today at 4:00 PM ET. Access the event here CAMBRIDGE, Mass.
